Saltar al contenido
Merck

IL-35 subunit EBI3 alleviates bleomycin-induced pulmonary fibrosis via suppressing DNA enrichment of STAT3.

Respiratory research (2021-10-30)
Donghong Chen, Guofeng Zheng, Qing Yang, Le Luo, Jinglian Shen
RESUMEN

IL-35 subunit EBI3 is up-regulated in pulmonary fibrosis tissues. In this study, we investigated the pathological role of EBI3 in pulmonary fibrosis and dissected the underlying molecular mechanism. Bleomycin-induced pulmonary fibrosis mouse model was established, and samples were performed gene expression analyses through RNAseq, qRT-PCR and Western blot. Wild type and EBI3 knockout mice were exposed to bleomycin to investigate the pathological role of IL-35, via lung function and gene expression analyses. Primary lung epithelial cells were used to dissect the regulatory mechanism of EBI3 on STAT1/STAT4 and STAT3. IL-35 was elevated in both human and mouse with pulmonary fibrosis. EBI3 knockdown aggravated the symptoms of pulmonary fibrosis in mice. EBI3 deficiency enhanced the expressions of fibrotic and extracellular matrix-associated genes. Mechanistically, IL-35 activated STAT1 and STAT4, which in turn suppressed DNA enrichment of STAT3 and inhibited the fibrosis process. IL-35 might be one of the potential therapeutic targets for bleomycin-induced pulmonary fibrosis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Sulfato de bleomicina from Streptomyces verticillus, crystalline, 1.5-2.0 U/mg
Sigma-Aldrich
Interleukin-6 human, IL-6, recombinant, expressed in HEK 293 cells, suitable for cell culture
Sigma-Aldrich
IL-35 (mouse): FC (human), recombinant, expressed in CHO cells